ACAD Latest Headlines

Canaccord Genuity Sticks to Their Buy Rating for ACADIA Pharmaceuticals (ACAD)

at www.tipranks.com (Fri, 6-Nov 9:56 AM)

Acadia raises 2026 DAYBUE guidance after Q3 sales jump to $140 million

Market Chameleon (Thu, 5-Nov 11:15 AM)

Analysts Offer Insights on Healthcare Companies: ACADIA Pharmaceuticals (ACAD), Edwards Lifesciences (EW) and PROCEPT BioRobotics (PRCT)

at www.tipranks.com (Thu, 5-Nov 6:00 PM)

Analysts Offer Insights on Healthcare Companies: ACADIA Pharmaceuticals (ACAD), Cytek Biosciences (CTKB) and Mineralys Therapeutics, Inc. (MLYS)

at www.tipranks.com (Thu, 5-Nov 9:02 AM)

Analysts Offer Insights on Healthcare Companies: Envista Holdings (NVST), ACADIA Pharmaceuticals (ACAD) and Arcutis Biotherapeutics (ARQT)

at www.tipranks.com (Thu, 5-Nov 8:50 AM)

BMO Capital Reaffirms Their Buy Rating on ACADIA Pharmaceuticals (ACAD)

at www.tipranks.com (Thu, 5-Nov 8:28 AM)

Analysts Offer Insights on Healthcare Companies: Urogen Pharma (URGN), Alnylam Pharma (ALNY) and ACADIA Pharmaceuticals (ACAD)

at www.tipranks.com (Thu, 5-Nov 8:20 AM)

Analysts Have Conflicting Sentiments on These Healthcare Companies: ACADIA Pharmaceuticals (ACAD), Rockwell Med (RMTI) and Tecan Group AG (OtherTCHBF)

at www.tipranks.com (Thu, 5-Nov 8:10 AM)

ACAD Slides as Remlifanserin Misses Primary Endpoint (p=0.0603) Despite Nominal Win on CGI-S-ADP

Market Chameleon (Thu, 24-Sep 11:48 AM)

ACAD advances remlifanserin into refined Phase 3 plan after 60 mg dose showed a widening week-6 separation vs placebo

Market Chameleon (Thu, 24-Sep 7:30 AM)